Vitamin K2 is one of the most underappreciated nutrients in modern medicine — and one of the most consequential. While Vitamin K1 (phylloquinone) is well known for its role in blood clotting, Vitamin K2 (menaquinone) serves an entirely different and equally critical function: it activates proteins that direct calcium to where it belongs — bones and teeth — and away from where it causes harm — arteries, kidneys, and soft tissues. Without adequate K2, calcium supplementation and even high-dose Vitamin D3 can paradoxically accelerate arterial calcification.
K1 vs. K2: Fundamentally Different Roles
Vitamin K1 is found in leafy green vegetables and is primarily used by the liver for coagulation factor synthesis. Vitamin K2 is found in fermented foods and animal products, and is used by extrahepatic tissues — particularly bone, arteries, and the kidneys — to activate K-dependent proteins that regulate calcium metabolism. The two forms are not interchangeable for these tissue-specific functions.
MK-4 vs. MK-7: Why MK-7 Is Superior
Vitamin K2 exists in several menaquinone forms (MK-4 through MK-13), differing in the length of their isoprenoid side chain. The two most clinically relevant supplemental forms are:
- MK-4 (menatetrenone): Short half-life (~1 hour), requires multiple daily doses, found in animal products
- MK-7 (menaquinone-7): Long half-life (~72 hours), once-daily dosing is effective, derived from natto (fermented soybeans) or synthesized; achieves significantly higher and more sustained tissue concentrations
MK-7 is the preferred supplemental form due to its superior pharmacokinetics and demonstrated efficacy in clinical trials at doses as low as 45–180 mcg/day.
The K-Dependent Proteins: How K2 Works
Vitamin K2 activates proteins through a process called gamma-carboxylation — adding carboxyl groups to glutamic acid residues, enabling these proteins to bind calcium. The two most important K2-dependent proteins are:
1. Osteocalcin (Bone Gla Protein)
Osteocalcin is produced by osteoblasts (bone-building cells) and, when activated by K2, binds calcium and incorporates it into the hydroxyapatite crystal matrix of bone. Undercarboxylated osteocalcin (ucOC) — the inactive form produced in K2 deficiency — cannot bind calcium and is associated with reduced bone mineral density and increased fracture risk. K2 supplementation significantly reduces ucOC levels and improves bone quality.
2. Matrix Gla Protein (MGP)
MGP is the most potent known inhibitor of arterial calcification. Produced by vascular smooth muscle cells and chondrocytes, MGP — when activated by K2 — binds calcium crystals in arterial walls and prevents their deposition. Uncarboxylated MGP (ucMGP) is a validated biomarker of K2 deficiency and a strong predictor of cardiovascular mortality. The Rotterdam Study demonstrated that high dietary K2 intake was associated with a 57% reduction in cardiovascular mortality and significantly less aortic calcification.
Clinical Evidence for Vitamin K2 MK-7
Bone Health
- The MenaQ7 trial (3-year RCT) demonstrated that 180 mcg/day MK-7 significantly improved bone mineral density and bone strength in postmenopausal women compared to placebo
- K2 supplementation reduces fracture risk and improves bone quality independent of calcium intake
- K2 works synergistically with Vitamin D3 — D3 increases calcium absorption while K2 ensures proper calcium deposition
Cardiovascular Protection
- High ucMGP levels (indicating K2 deficiency) are associated with increased arterial stiffness, coronary artery calcification, and cardiovascular events
- MK-7 supplementation (180 mcg/day for 3 years) significantly reduced arterial stiffness in healthy postmenopausal women (Knapen et al., 2015)
- K2 intake is inversely associated with coronary heart disease in multiple large prospective cohort studies
Dental Health
K2 activates osteocalcin in odontoblasts (dentin-producing cells), supporting tooth mineralization and potentially reducing cavity risk. This is the mechanism behind Weston A. Price's historical observations linking "Activator X" (now identified as K2) to dental health in traditional populations.
The D3 + K2 Partnership
Vitamin D3 and K2 must be understood as a functional pair:
- D3 dramatically increases intestinal calcium absorption
- Without K2, this additional calcium has no guidance system and may deposit in arteries and soft tissues
- K2 activates MGP and osteocalcin to direct calcium appropriately
- High-dose D3 supplementation without adequate K2 may increase cardiovascular risk — K2 is the essential safety partner
Dietary Sources of Vitamin K2
- Natto (fermented soybeans) — by far the richest source (~1,000 mcg MK-7 per 100g)
- Hard cheeses — Gouda and Brie contain meaningful MK-8 and MK-9
- Egg yolks — primarily MK-4
- Butter and ghee from grass-fed animals
- Chicken liver — MK-4
- Fermented vegetables — modest amounts
Western diets are typically very low in K2 — natto is rarely consumed outside Japan, and most dairy is from grain-fed animals with lower K2 content.
Supplementation: Dosing & Safety
- General maintenance: 90–120 mcg MK-7/day
- Therapeutic (bone/cardiovascular support): 180–360 mcg MK-7/day
- Take with a fat-containing meal (fat-soluble)
- Warfarin interaction: K2 can interfere with warfarin (vitamin K antagonist) — individuals on anticoagulant therapy must consult their physician before supplementing
- No upper tolerable intake level has been established for K2 — it has an excellent safety profile at supplemental doses
The Bottom Line
Vitamin K2 MK-7 is the essential calcium traffic director — ensuring that calcium builds strong bones and teeth rather than calcifying arteries and soft tissues. It is the critical partner to Vitamin D3 and calcium supplementation, and its deficiency is implicated in osteoporosis, arterial calcification, and cardiovascular disease. For anyone supplementing Vitamin D3 at meaningful doses, K2 MK-7 is not optional — it is essential.
0 comments